Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Wolter

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Onkologie|February 8, 2012
Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment optionPatrick Schöffski, Linda Cerbone, Pascal Wolter, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 8, 2013
Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot studyKatja De Paepe, Charlotte Bevernage, Frederik De Keyzer, et al.
Drugs & Aging|October 8, 2015
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older PatientsAljosja Rogiers, Joost J van den Oord, Marjan Garmyn, et al.
Melanoma Research|January 26, 2019
Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcomeVivien Marasigan, Canan Güvenç, Joost J van den Oord, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 16, 2018
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRIKatja N De Paepe, Frederik De Keyzer, Pascal Wolter, et al.
Clinical Genitourinary Cancer|July 19, 2016
A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation TherapyCiska-Anne Van Keerberghen, Simon Van Wambeke, Pascal Wolter, et al.
Melanoma Research|August 12, 2017
Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsEAljosja Rogiers, Sara Vander Borght, Krizia Tuand, et al.
Clinical Genitourinary Cancer|May 28, 2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysisBenoit Beuselinck, Evelyne Lerut, Pascal Wolter, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2015
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitorAnne Sacré, Philippe Barthélémy, Clement Korenbaum, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Onkologie|February 8, 2012
Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment optionPatrick Schöffski, Linda Cerbone, Pascal Wolter, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 8, 2013
Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot studyKatja De Paepe, Charlotte Bevernage, Frederik De Keyzer, et al.
Drugs & Aging|October 8, 2015
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older PatientsAljosja Rogiers, Joost J van den Oord, Marjan Garmyn, et al.
Melanoma Research|January 26, 2019
Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcomeVivien Marasigan, Canan Güvenç, Joost J van den Oord, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 16, 2018
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRIKatja N De Paepe, Frederik De Keyzer, Pascal Wolter, et al.
Clinical Genitourinary Cancer|July 19, 2016
A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation TherapyCiska-Anne Van Keerberghen, Simon Van Wambeke, Pascal Wolter, et al.
Melanoma Research|August 12, 2017
Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsEAljosja Rogiers, Sara Vander Borght, Krizia Tuand, et al.
Clinical Genitourinary Cancer|May 28, 2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysisBenoit Beuselinck, Evelyne Lerut, Pascal Wolter, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2015
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitorAnne Sacré, Philippe Barthélémy, Clement Korenbaum, et al.
Pageof 6